Semaglutide and Cardiovascular Outcomes in Patients With Overweight or Obesity Who Do Not Have Diabetes

被引：0

作者：

Lincoff, Abraham M. ^{[1
]}

Brown-Frandsen, Kirstine ^{[2
]}

Colhoun, Helen M. ^{[3
]}

Deanfield, John ^{[4
]}

Emerson, Scott S. ^{[5
]}

Esbjerg, Sille ^{[6
]}

Hardt-Lindberg, Soren ^{[7
]}

Hovingh, G. Kees ^{[8
]}

Kahn, Steven E. ^{[9
,10
]}

Kushner, Robert F. ^{[11
]}

Lingvay, Ildiko ^{[12
]}

Oral, Tugce Kalayci ^{[8
]}

Michelsen, Marie M. ^{[13
]}

Plutzky, Jorge ^{[14
]}

Tornoee, Christoffer W. ^{[15
]}

Ryan, Donna H. ^{[16
]}

机构：

[1] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44106 USA

[2] Novo Nordisk AS, Business Dev, Soborg, Denmark

[3] Univ Edinburgh, Inst Genet & Canc, Edinburgh, Midlothian, Scotland

[4] UCL, Dept Clin Sci, London, England

[5] Univ Washington, Dept Biostat, Seattle, WA 98195 USA

[6] Novo Nordisk AS, Dept Biostat, Soborg, Denmark

[7] Novo Nordisk AS, Project Management CKAD 5, Soborg, Denmark

[8] Novo Nordisk AS, Global Med Affairs, Soborg, Denmark

[9] VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA

[10] Univ Washington, Seattle, WA 98195 USA

[11] Northwestern Univ, Dept Med & Med Educ, Chicago, IL 60611 USA

[12] UT SouthWestern Med Ctr, Dept Internal Med Endocrinol, Dallas, TX USA

[13] Novo Nordisk AS, Med & Sci, Soborg, Denmark

[14] Harvard Med Sch, Brigham & Womens Hosp, Cardiovasc Med Div, Boston, MA 02115 USA

[15] Novo Nordisk AS, Obes Liver Dis & Devices, Soborg, Denmark

[16] Pennington Biomed Res Ctr, Clin Res, 6400 Perkins Rd, Baton Rouge, LA 70808 USA

来源：

CIRCULATION | 2023年 / 148卷 / 25期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

22962

引用

页码：E283 / E283

页数：1

共 50 条

[41] THE COST-EFFECTIVENESS OF SEMAGLUTIDE 2.4MG IN PATIENTS WITH OVERWEIGHT/OBESITY AND CARDIOVASCULAR DISEASE FROM THE SELECT TRIAL
McEwan, P.
Bog, M.
Faurby, M.
Foos, V
Lingvay, I
Lubker, C.
Miller, R.
Toliver, J.
Yeates, F.
Lincoff, A. M.
VALUE IN HEALTH, 2024, 27 (06) : S148 - S148
[42] Cost-Effectiveness of Semaglutide in Patients With Obesity and Cardiovascular Disease
Rennert-May, Elissa
Manns, Braden
Clement, Fiona
Spackman, Eldon
Collister, David
Sumner, Glen
Leal, Jenine
Miller, Robert J. H.
Chew, Derek S.
CANADIAN JOURNAL OF CARDIOLOGY, 2025, 41 (01) : 128 - 136
[43] Effectiveness of Semaglutide in Overweight or Obese Patients With IgA Nephropathy Without Diabetes
Si, Feng-Lei
Tang, Chen
Chen, Pei
Hou, Wan-Yin
Yang, Hong-Yu
Lv, Ji-Cheng
Shi, Su-Fang
Zhou, Xu-Jie
Liu, Li-Jun
Zhang, Hong
NEPHROLOGY, 2025, 30 (04)
[44] Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes
Mcewan, Phil
Bog, Martin
Faurby, Mads
Foos, Volker
Lingvay, Ildiko
Luebker, Christopher
Miller, Ryan
Toliver, Joshua C.
Yeates, Florian
Lincoff, A. Michael
JOURNAL OF MEDICAL ECONOMICS, 2025, 28 (01) : 268 - 278
[45] CLINICAL PARAMETERS ASSOCIATED WITH SEMAGLUTIDE INTOLERANCE IN PATIENTS WITH DIABETES AND OBESITY
Ghusn, Wissam
Anazco, Diego
Fansa, Sima
Tama, Elif
Cifuentes, Lizeth
Campos, Alejandro
Gala, Khushboo
Calderon, Gerardo
Hurtado, Maria D.
Acosta, Andres
GASTROENTEROLOGY, 2024, 166 (05) : S591 - S592
[46] Do Adult Patients With Type 1 or 2 Diabetes Who Present to the Emergency Department With Hyperglycemia Have Improved Outcomes if They Have Access to Specialized Diabetes Care?
Yan, Justin W.
Liu, Selina
Van Aarsen, Kristine
Columbus, Melanie P.
Spaic, Tamara
CANADIAN JOURNAL OF DIABETES, 2021, 45 (01) : 59 - 63
[47] Body weight time in target range and cardiovascular outcomes in adults with overweight/obesity and type 2 diabetes
Liu, Menghui
Xu, Xingfeng
Chen, Xiaohong
Guo, Yue
Zhang, Shaozhao
Lin, Yifen
Zhou, Huimin
Li, Miaohong
Xie, Peihan
Xia, Wenhao
Wang, Lichun
Zhuang, Xiaodong
Liao, Xinxue
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2023, 30 (12) : 1263 - 1271
[48] Do Patients with Diabetes Mellitus and Polytrauma Continue to Have Worse Outcomes?
Tebby, James
Giannoudis, Vasileios P.
Wakefield, Sophia M.
Lecky, Fiona
Bouamra, Omar
Giannoudis, Peter V.
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (10)
[49] Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial
Kahn, Steven E.
Deanfield, John E.
Jeppesen, Ole Kleist
Emerson, Scott S.
Boesgaard, Trine Wellov
Colhoun, Helen M.
Kushner, Robert F.
Lingvay, Ildiko
Burguera, Bartolome
Gajos, Grzegorz
Horn, Deborah Bade
Hramiak, Irene M.
Jastreboff, Ania M.
Kokkinos, Alexander
Maeng, Michael
Matos, Ana Laura S. A.
Tinahones, Francisco J.
Lincoff, A. Michael
Ryan, Donna H.
DIABETES CARE, 2024, 47 (08)
[50] In adults with overweight or obesity and CVD, but without diabetes, semaglutide reduced MACE at a mean 40 mo
Koutroumpakis, Efstratios
Deswal, Anita
ANNALS OF INTERNAL MEDICINE, 2024, 177 (03) : JC31 - JC31

← 1 2 3 4 5 →